Century Therapeutics, Inc. Capital Expenditures
Century Therapeutics, Inc. (IPSC) reported Capital Expenditures of $1.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $694.00K, a 118.93% increase year-over-year.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $584.00K, a 22.95% increase year-over-year.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was -$139.00K.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $195.00K.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $848.00K, a 450.65% increase from fiscal 2024.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $154.00K, a 98.88% decline from fiscal 2023.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $13.74M, a 55.12% decline from fiscal 2022.
- Century Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $30.60M, a 31.95% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $694.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.28M 10-Q · filed 2026-08-12 | $1.14M derived: sum of 3 quarters · filed 2026-08-12 | $1.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $584.00K 10-Q · filed 2026-05-13 | $445.00K derived: sum of 2 quarters · filed 2026-05-13 | $640.00K derived: sum of 3 quarters · filed 2026-05-13 | $957.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $56.00K derived: sum of 2 quarters · filed 2026-03-12 | $373.00K derived: sum of 3 quarters · filed 2026-08-12 | $848.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $195.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $512.00K derived: sum of 2 quarters · filed 2026-08-12 | $987.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $317.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $792.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $475.00K 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $154.00K 10-K · filed 2026-03-12 | |||
| 2024-06-30 | $265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $804.00K 10-Q · filed 2025-08-14 | $1.78M derived: sum of 3 quarters · filed 2025-08-14 | $5.05M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $539.00K 10-Q · filed 2025-05-15 | $1.52M derived: sum of 2 quarters · filed 2025-05-15 | $4.78M derived: sum of 3 quarters · filed 2025-05-15 | $9.28M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $980.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $4.25M derived: sum of 2 quarters · filed 2025-03-19 | $8.74M derived: sum of 3 quarters · filed 2025-03-19 | $13.74M 10-K · filed 2025-03-19 |
| 2023-09-30 | $3.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.76M derived: sum of 2 quarters · filed 2024-11-05 | $12.76M 10-Q · filed 2024-11-05 | $19.02M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $9.49M 10-Q · filed 2024-08-08 | $15.76M derived: sum of 3 quarters · filed 2024-08-08 | $25.57M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.99M 10-Q · filed 2024-05-09 | $11.26M derived: sum of 2 quarters · filed 2024-05-09 | $21.07M derived: sum of 3 quarters · filed 2024-05-09 | $31.53M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $16.08M derived: sum of 2 quarters · filed 2024-03-14 | $26.54M derived: sum of 3 quarters · filed 2024-03-14 | $30.60M 10-K · filed 2024-03-14 |
| 2022-09-30 | $9.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $20.27M derived: sum of 2 quarters · filed 2023-11-09 | $24.34M 10-Q · filed 2023-11-09 | $41.06M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $10.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $14.52M 10-Q · filed 2023-08-09 | $31.25M derived: sum of 3 quarters · filed 2023-08-09 | $46.98M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $4.07M 10-Q · filed 2023-05-11 | $20.79M derived: sum of 2 quarters · filed 2023-05-11 | $36.52M derived: sum of 3 quarters · filed 2023-05-11 | $47.15M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $16.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $32.46M derived: sum of 2 quarters · filed 2023-03-16 | $43.09M derived: sum of 3 quarters · filed 2023-03-16 | $44.97M 10-K · filed 2023-03-16 |
| 2021-09-30 | $15.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $26.36M derived: sum of 2 quarters · filed 2022-11-10 | $28.25M 10-Q · filed 2022-11-10 | $30.15M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $10.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $12.51M 10-Q · filed 2022-08-11 | $14.42M derived: sum of 3 quarters · filed 2022-08-11 | $18.92M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.88M 10-Q · filed 2022-05-16 | $3.79M derived: sum of 2 quarters · filed 2022-05-16 | $8.29M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $6.41M derived: sum of 2 quarters · filed 2022-03-17 | $9.82M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $4.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $7.92M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $3.42M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |